Bret Stysly, MD
Internal Medicine · Augusta, GANPI 1104188416
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (43.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 82.8% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $5,414, 3.5 times the $1,556 reported in 2019. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $137.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- Olympus Corporation Of The Americas$911
- Veran Medical Technologies, Inc.$444
- Boehringer Ingelheim$232
- Insmed, Inc.$81
- Takeda Pharmaceuticals U.S.A., Inc.$78
- plus $348 from 12 others
What the payments were for
- Speaking & faculty fees$4,50037%
- Travel & lodging$5,25043%
- Food & beverage$2,32619%
- Education$681%
- Gifts$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 40 | $10,105 |
| Olympus Corporation Of The Americas | 8 | $911 |
| Veran Medical Technologies, Inc. | 3 | $444 |
| Boehringer Ingelheim | 10 | $232 |
| Insmed, Inc. | 5 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $78 |
| GSK | 4 | $73 |
| Sanofi-aventis U.S. LLC | 3 | $67 |
| Amgen | 1 | $34 |
| Pulmonx Corporation | 1 | $28 |
| Shire North American Group Inc | 2 | $27 |
| Mylan Specialty L.p. | 1 | $20 |
| Grifols USA, LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Pfizer | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Electromed, Inc. | 1 | $16 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,200 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 625 | $468,224 |
| OfevNintedanib Esylate | 11 | $141,662 |
| Dupixent PenDupilumab | 28 | $104,424 |
| Spiriva RespimatTiotropium Bromide | 175 | $102,391 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 162 | $98,488 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 94 | $69,674 |
| Spiriva HandihalerTiotropium Bromide | 80 | $65,148 |
| Breo ElliptaFluticasone/Vilanterol | 128 | $63,061 |
| TezspireTezepelumab-Ekko | 11 | $50,274 |
| Dupixent SyringeDupilumab | 13 | $45,661 |
| Incruse ElliptaUmeclidinium Bromide | 71 | $34,110 |
| SymbicortBudesonide/Formoterol Fumarate | 109 | $28,693 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 216 | $27,108 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 38 | $24,071 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $23,920 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $73 | $643,138947 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $232 | $366,611386 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Augusta
- Oladapo FawibeAugusta$79K
- Twinkle SinghAugusta$23K
- Kayla ShahbazianAugusta$21K
- Koosh DesaiAugusta$19K
- Sheng WangAugusta$19K
- Eman KaldasAugusta$18K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.